Intravitreal anti-vascular endothelial growth factor (bevacizumab) in nanophthalmic exudative macular detachment – A new treatment modality
Journal of Ophthalmic Research and Practice · 2023
DOI: 10.25259/jorp_18_2023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ophthalmic Research and Practice, 2023. Verfasst von Satyen Deka und 1 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Nanophthalmic exudative macular retinal detachment is a known entity, till now the established treatment modality is Scleral Resection. This brief communication suggests a successful new modality of non-surgical, less invasive treatment approach of intravitreal anti-vascular endothelial growth factor in case of exudate macular detachment related to nanophthalmos.
Zitieren
APA
Deka, S., & Singh, V. (2023). Intravitreal anti-vascular endothelial growth factor (bevacizumab) in nanophthalmic exudative macular detachment – A new treatment modality. Journal of Ophthalmic Research and Practice. https://doi.org/10.25259/jorp_18_2023
Vancouver
Deka S, Singh V. Intravitreal anti-vascular endothelial growth factor (bevacizumab) in nanophthalmic exudative macular detachment – A new treatment modality. Journal of Ophthalmic Research and Practice. 2023. doi:10.25259/jorp_18_2023
BibTeX
@article{Deka2023,
author = {Deka, Satyen and Singh, Vajinder},
title = {Intravitreal anti-vascular endothelial growth factor (bevacizumab) in nanophthalmic exudative macular detachment – A new treatment modality},
journal = {Journal of Ophthalmic Research and Practice},
year = {2023},
doi = {10.25259/jorp_18_2023}
}
EUVIMED